234 related articles for article (PubMed ID: 12473171)
1. Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies.
Schairer C
Breast Cancer Res; 2002; 4(6):244-8. PubMed ID: 12473171
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-progestin replacement therapy: regulatory action needed.
Pike MC; Ross RK
Breast Cancer Res; 2002; 4(6):222-3. PubMed ID: 12473167
[TBL] [Abstract][Full Text] [Related]
3. More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Magnusson C; Persson I; Adami HO
J Natl Cancer Inst; 2000 Jul; 92(14):1183-4. PubMed ID: 10904095
[No Abstract] [Full Text] [Related]
4. Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy.
Lillie EO; Bernstein L; Ingles SA; Gauderman WJ; Rivas GE; Gagalang V; Krontiris T; Ursin G
Cancer Res; 2004 Feb; 64(4):1237-41. PubMed ID: 14973115
[TBL] [Abstract][Full Text] [Related]
5. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer.
Pike MC; Ross RK
Steroids; 2000; 65(10-11):659-64. PubMed ID: 11108873
[TBL] [Abstract][Full Text] [Related]
6. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
7. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins.
Topal NB; Ayhan S; Topal U; Bilgin T
J Obstet Gynaecol Res; 2006 Jun; 32(3):305-8. PubMed ID: 16764621
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer and hormone-replacement therapy: the Million Women Study.
Garton M
Lancet; 2003 Oct; 362(9392):1328; author reply 1330-1. PubMed ID: 14575985
[No Abstract] [Full Text] [Related]
9. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Dew JE; Wren BG; Eden JA
Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
[TBL] [Abstract][Full Text] [Related]
10. [Postmenopausal hormone therapy--an update. Benefit versus risk--important to identify women with increased breast cancer risk].
von Schoultz B
Lakartidningen; 2009 Aug 19-25; 106(34):2041-2. PubMed ID: 19769143
[No Abstract] [Full Text] [Related]
11. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement.
Persson I; Weiderpass E; Bergkvist L; Bergström R; Schairer C
Cancer Causes Control; 1999 Aug; 10(4):253-60. PubMed ID: 10482483
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.
Fournier A; Berrino F; Riboli E; Avenel V; Clavel-Chapelon F
Int J Cancer; 2005 Apr; 114(3):448-54. PubMed ID: 15551359
[TBL] [Abstract][Full Text] [Related]
13. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
[TBL] [Abstract][Full Text] [Related]
14. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy.
Magnusson C; Baron JA; Correia N; Bergström R; Adami HO; Persson I
Int J Cancer; 1999 May; 81(3):339-44. PubMed ID: 10209946
[TBL] [Abstract][Full Text] [Related]
15. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.
Campagnoli C; Clavel-Chapelon F; Kaaks R; Peris C; Berrino F
J Steroid Biochem Mol Biol; 2005 Jul; 96(2):95-108. PubMed ID: 15908197
[TBL] [Abstract][Full Text] [Related]
16. Estrogen with interrupted progestin HRT: a review of experimental and clinical studies.
Casper RF
Maturitas; 2000 Feb; 34(2):97-108. PubMed ID: 10714903
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
Glass AG; Lacey JV; Carreon JD; Hoover RN
J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
[TBL] [Abstract][Full Text] [Related]
18. Breast-cancer risk: higher with estrogen-progestin than estrogen alone.
Miller JL
Am J Health Syst Pharm; 2000 Apr; 57(7):635-6. PubMed ID: 10768814
[No Abstract] [Full Text] [Related]
19. Postmenopausal hormone therapy and breast cancer.
Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
[TBL] [Abstract][Full Text] [Related]
20. Re: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Kuller LH
J Natl Cancer Inst; 2000 Jul; 92(13):1100-1. PubMed ID: 10880556
[No Abstract] [Full Text] [Related]
[Next] [New Search]
